Article Text

Download PDFPDF
Articles of interest in other scholarly journals
  1. Elaine Boland
  1. Palliative Medicine, Hull and East Yorkshire Hospitals NHS Trust, Hull HU3 2JZ, UK
  1. Correspondence to Dr Elaine Boland, Palliative Medicine, Hull and East Yorkshire Hospitals NHS Trust, Hull HU3 2JZ, UK; Elaine.Boland{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later

  • Sebastiano Mercadante, Franco Marinangeli, Francesco Masedu, et al. J Pain Symptom Manage. 2018;56:902–7.

This open-label study compared the use of hyoscine butylbromide prophylactically in dying patients with a reduced level of consciousness (n= 51) versus giving hyoscine butylbromide to dying patients only once they developed noisy respiratory tract secretions (n=81). Patients were administered 20 mg of hyoscine butylbromide as a subcutaneous or intravenous bolus, followed by 60 mg/24 hours. In patients who were given prophylactic hyoscine butylbromide, 5.9 % developed death rattle while 60.5 % had death rattle in the group who were given hyoscine butylbromide once death rattle was established. There was a significant difference for the onset of death rattle in both groups (median time 12 hours vs 36 hours in the …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.